APLMNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as APLMW
Apollomics Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 24, 2026
$22.05+0.95 (+4.49%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Apollomics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
5 buys · 0 sales
Net bought $8.25M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| King Regent Management Limited | 901,362 | 41.80% | 13D (active) amendment | Mar 30, 2026 |
| Hung-Wen Chen | 1,453,029 | 49.76% | 13D (active) amendment | Aug 14, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Yi-Kuei Chen | Chief Operating Officer, Director | 141,348 | Sep 24, 2026 |
| Hung-Wen Chen | Chief Executive Officer, Director, 10% owner | 1,453,029 | Sep 17, 2026 |
| Peter Kuan-How Lin | Chief Financial Officer | 58,979 | Sep 24, 2026 |
| Hung Hsien Yen | Director | 500 | Sep 24, 2026 |
| Ya-Chi Huang | Director | 1,500 | Sep 17, 2026 |
| Hsien-Shu Tsai | Director | 2,000 | Sep 17, 2026 |
| Hong-Jung Chen | Director | 4,120 | Sep 17, 2026 |
| Yi-An Chu | Director | 1,500 | Jun 16, 2026 |
| Chen-Huan Jan | Director | 1,500 | Jun 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter Kuan-How Lin Chief Financial Officer | Sep 15, 2026 | Option exercise | +10,000 | – | – | 58,979 |
| Peter Kuan-How Lin Chief Financial Officer | Sep 15, 2026 | Tax withholding | −3,416 | $24.02 | $82.05K | 55,563 |
| Yi-Kuei Chen Chief Operating Officer, Director | Sep 15, 2026 | Option exercise | +5,000 | – | – | 20,100 |
| Hung Hsien Yen Director | Sep 15, 2026 | Option exercise | +500 | – | – | 500 |
| Yi-Kuei Chen Chief Operating Officer, Director | Sep 15, 2026 | Option exercise | +5,000 | – | – | 20,100 |
| Hong-Jung Chen Director | Sep 15, 2026 | Option exercise | +500 | – | – | 4,120 |
| Hsien-Shu Tsai Director | Sep 15, 2026 | Option exercise | +500 | – | – | 2,000 |
| Hung-Wen Chen Chief Executive Officer, Director, 10% owner | Sep 15, 2026 | Option exercise | +5,000 | – | – | 423,334 |
| Peter Kuan-How Lin Chief Financial Officer, Director | Sep 15, 2026 | Option exercise | +10,000 | – | – | 58,979 |
| Peter Kuan-How Lin Chief Financial Officer, Director | Sep 15, 2026 | Tax withholding | −3,416 | $24.02 | $82.05K | 55,563 |
| Hung Hsien Yen Director | Sep 15, 2026 | Option exercise | +500 | – | – | 500 |
| Ya-Chi Huang Director | Aug 17, 2026 | Option exercise | +500 | – | – | 1,500 |
| Peter Kuan-How Lin Chief Financial Officer | Aug 14, 2026 | Buy | +26,667 | $15.00 | $400.01K | 48,979 |
| Yi-Kuei Chen Chief Operating Officer, Director | Aug 14, 2026 | Buy | +20,000 | $15.00 | $300.00K | 121,248 |
| Hung-Wen Chen Chief Executive Officer, Director | Aug 14, 2026 | Buy | +103,333 | $15.00 | $1.55M | 418,334 |
| Hung-Wen Chen Chief Executive Officer, Director | Aug 14, 2026 | Buy | +166,667 | $12.00 | $2.00M | 315,001 |
| Hung-Wen Chen Chief Executive Officer, Director | Aug 14, 2026 | Buy | +266,667 | $15.00 | $4.00M | 1,029,695 |
| Peter Kuan-How Lin Chief Financial Officer, Director | Jun 15, 2026 | Option exercise | +10,000 | – | – | 25,900 |
| Peter Kuan-How Lin Chief Financial Officer, Director | Jun 15, 2026 | Tax withholding | −3,588 | $13.85 | $49.69K | 22,312 |
| Hsien-Shu Tsai Director | Jun 15, 2026 | Option exercise | +500 | – | – | 1,500 |
| Yi-Kuei Chen Chief Operating Officer, Director | Jun 15, 2026 | Option exercise | +5,000 | – | – | 15,000 |
| Chen-Huan Jan Director | Jun 15, 2026 | Option exercise | +500 | – | – | 1,500 |
| Hong-Jung Chen Director | Jun 15, 2026 | Option exercise | +500 | – | – | 3,620 |
| Hung-Wen Chen Chief Executive Officer, Director | Jun 15, 2026 | Option exercise | +5,000 | – | – | 148,334 |
| Yi-An Chu Director | Jun 15, 2026 | Option exercise | +500 | – | – | 1,500 |
| Ya-Chi Huang Director | May 17, 2026 | Option exercise | +500 | – | – | 1,000 |
| Peter Kuan-How Lin Chief Financial Officer | Mar 31, 2026 | Tax withholding | −3,582 | $15.85 | $56.77K | 12,318 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Asia Partners II, L.P. Shareholder | Nov 27, 2023 | 9,515,756 | $11.32M | Nov 27, 2023 | Business combination |
| OrbiMed Asia Partners II, L.P. Shareholder | Nov 16, 2023 | 16,183,185 | $28.64M | Nov 16, 2023 | Business combination |
| OrbiMed Asia Partners, L.P. Shareholder | Oct 30, 2023 | 915,670 | $789.31K | Oct 30, 2023 | Business combination |
| OrbiMed Asia Partners, L.P. Shareholder | Oct 5, 2023 | 894,807 | $2.86M | Oct 5, 2023 | Business combination |